A Controlled Trial of Baclofen in Children with Cerebral Palsy
- 1 January 1973
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 1 (2) , 398-404
- https://doi.org/10.1177/030006057300100203
Abstract
A double-blind crossover trial against placebo was conducted to assess the effects of the GABA derivative, baclofen, on the disabilities due to muscle spasticity in twenty children suffering from cerebral palsy. Baclofen performed very significantly better than placebo in reducing spasticity and significantly better than placebo in allowing both active and passive limb movements to be carried out. Notable improvement was also seen in scissoring. Side-effects were minimal and responded promptly to dose reduction. The evaluation of drug effects on muscle spasticity and the pharmacodynamics of baclofen are discussed. Recommendations are made regarding dosage of baclofen in childhood.This publication has 6 references indexed in Scilit:
- Sites of Action of a New Muscle Relaxant (Baclofen, Lioresal®, Ciba 34 647–Ba)Journal of International Medical Research, 1974
- Gamma-Aminobutyric Acid Antagonism and Presynaptic Inhibition in the Frog Spinal CordScience, 1972
- Baclofen in the Treatment of SpasticityBMJ, 1971
- Spasticity [Abridged]Proceedings of the Royal Society of Medicine, 1970
- A new agent for the control of spasticityJournal of Neurology, Neurosurgery & Psychiatry, 1970
- GABA DERIVATIVE IN SPASTICITY (β-(4-Chlorophenyl)-γ-Aminobutyric Acid, Ciba 34.647-Bα)Acta Neurologica Scandinavica, 1970